HVO vs. OXB, AVCT, BVXP, 4BB, FUM, SCLP, FARN, POLB, ETX, and PRTC
Should you be buying hVIVO stock or one of its competitors? The main competitors of hVIVO include Oxford Biomedica (OXB), Avacta Group (AVCT), Bioventix (BVXP), 4basebio (4BB), Futura Medical (FUM), Scancell (SCLP), Faron Pharmaceuticals Oy (FARN), Poolbeg Pharma (POLB), e-therapeutics (ETX), and PureTech Health (PRTC). These companies are all part of the "biotechnology" industry.
Oxford Biomedica (LON:OXB) and hVIVO (LON:HVO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk, valuation, dividends and media sentiment.
Oxford Biomedica has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, hVIVO has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500.
Oxford Biomedica presently has a consensus target price of GBX 498.75, suggesting a potential upside of 126.70%. Given hVIVO's higher possible upside, research analysts plainly believe Oxford Biomedica is more favorable than hVIVO.
58.1% of Oxford Biomedica shares are held by institutional investors. Comparatively, 14.0% of hVIVO shares are held by institutional investors. 16.2% of Oxford Biomedica shares are held by insiders. Comparatively, 39.2% of hVIVO shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
hVIVO has a net margin of 4.75% compared to hVIVO's net margin of -51.78%. Oxford Biomedica's return on equity of 13.55% beat hVIVO's return on equity.
Oxford Biomedica received 235 more outperform votes than hVIVO when rated by MarketBeat users. However, 69.89% of users gave hVIVO an outperform vote while only 66.79% of users gave Oxford Biomedica an outperform vote.
In the previous week, hVIVO had 2 more articles in the media than Oxford Biomedica. MarketBeat recorded 2 mentions for hVIVO and 0 mentions for Oxford Biomedica. Oxford Biomedica's average media sentiment score of 0.57 beat hVIVO's score of 0.00 indicating that hVIVO is being referred to more favorably in the news media.
hVIVO has lower revenue, but higher earnings than Oxford Biomedica.
Summary
hVIVO beats Oxford Biomedica on 10 of the 16 factors compared between the two stocks.
Get hVIVO News Delivered to You Automatically
Sign up to receive the latest news and ratings for HVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
